{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:46:24Z","timestamp":1791927984855,"version":"4.3.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Renal hypouricemia (RHUC) is an inherited renal tubular disorder characterized by low serum uric acid levels and excessive urinary uric acid excretion due to impaired urate reabsorption in proximal tubules. Type 1 RHUC (RHUC1) is caused by pathogenic variants in\n                    <jats:italic>URAT1\/SLC22A12<\/jats:italic>\n                    . In Japanese patients, recurrent variants such as W258X and R90H account for a substantial proportion of RHUC1 cases; however, the clinical significance of rare\n                    <jats:italic>URAT1<\/jats:italic>\n                    variant combinations remains incompletely understood. A 69-year-old woman was referred to our hospital for evaluation of renal dysfunction and hypouricemia. Laboratory examination revealed severe hypouricemia (serum uric acid, 0.7\u00a0mg\/dL) and markedly increased urinary uric acid excretion (Cua\/Ccr, 60.5%). She had chronic kidney disease (CKD) stage G3b and a renal stone. Genetic analysis identified two heterozygous variants, A209V and F379L, in\n                    <jats:italic>URAT1\/SLC22A12<\/jats:italic>\n                    gene. The variants were considered likely to represent compound heterozygosity based on the clinical phenotype and their previously reported functional impairment. Although A209V and F379L have individually been reported to impair urate transport, the clinical phenotype associated with this variant combination has not been well characterized. The severe hypouricemia and excessive urinary uric acid excretion observed in this patient provide clinical evidence supporting the pathogenic significance of the A209V and F379L combination. The coexistence of nephrolithiasis and CKD further raises the possibility that excessive urinary urate excretion and stone formation may contribute to renal dysfunction. In addition, the improvement in stone-related urinary abnormalities during potassium citrate treatment suggests that urinary alkalization may be beneficial in the management of nephrolithiasis associated with RHUC.\n                  <\/jats:p>","DOI":"10.1007\/s13730-026-01189-0","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T05:00:16Z","timestamp":1791781216000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A case of renal hypouricemia type 1 associated with compound heterozygous URAT1\/SLC22A12 variants A209V and F379L: clinical evidence for their pathogenic significance"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0127-2118","authenticated-orcid":false,"given":"Naoyuki","family":"Otani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Takata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinobu","family":"Sugihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanari","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Fukuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiko","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyoshi","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Otsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiyoshi","family":"Ichida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Hisatome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"1189_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s13577-019-00239-3","volume":"32","author":"A Nakayama","year":"2019","unstructured":"Nakayama A, Matsuo H, Ohtahara A, et al. Clinical practice guideline for renal hypouricemia (1st edition). Hum Cell. 2019;32:83\u20137.","journal-title":"Hum Cell"},{"key":"1189_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/01.ASN.0000105320.04395.D0","volume":"15","author":"K Ichida","year":"2004","unstructured":"Ichida K, Hosoyamada M, Hisatome I, et al. Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol. 2004;15:164\u201373.","journal-title":"J Am Soc Nephrol"},{"key":"1189_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nature742","volume":"417","author":"A Enomoto","year":"2002","unstructured":"Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417:447\u201352.","journal-title":"Nature"},{"key":"1189_CR4","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.ajhg.2008.11.001","volume":"83","author":"H Matsuo","year":"2008","unstructured":"Matsuo H, Chiba T, Nagamori S, et al. Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am J Hum Genet. 2008;83:744\u201351.","journal-title":"Am J Hum Genet"},{"key":"1189_CR5","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3390\/biomedicines10030652","volume":"10","author":"N Otani","year":"2022","unstructured":"Otani N, Ouchi M, Misawa K, et al. Hypouricemia and urate transporters. Biomedicines. 2022;10:652.","journal-title":"Biomedicines"},{"key":"1189_CR6","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1534\/genetics.119.303006","volume":"214","author":"K Misawa","year":"2020","unstructured":"Misawa K, Hasegawa T, Mishima E, et al. Contribution of rare variants of the SLC22A12 gene to the missing heritability of serum urate levels. Genetics. 2020;214:1079\u201390.","journal-title":"Genetics"},{"key":"1189_CR7","doi-asserted-by":"publisher","first-page":"5224","DOI":"10.1093\/rheumatology\/keab327","volume":"60","author":"Y Toyoda","year":"2021","unstructured":"Toyoda Y, Kawamura Y, Nakayama A, et al. Substantial anti-gout effect conferred by common and rare dysfunctional variants of URAT1\/SLC22A12. Rheumatology (Oxford). 2021;60:5224\u201332.","journal-title":"Rheumatology (Oxford)"},{"key":"1189_CR8","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s00467-004-1424-1","volume":"19","author":"F Komoda","year":"2004","unstructured":"Komoda F, Sekine T, Inatomi J, et al. The W258X mutation in SLC22A12 is the predominant cause of Japanese renal hypouricemia. Pediatr Nephrol. 2004;19:728\u201333.","journal-title":"Pediatr Nephrol"},{"key":"1189_CR9","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1093\/rheumatology\/keab545","volume":"61","author":"A Nakayama","year":"2022","unstructured":"Nakayama A, Kawamura Y, Toyoda Y, et al. Genetic epidemiological analysis of hypouricaemia from 4993 Japanese on non-functional variants of URAT1\/SLC22A12 gene. Rheumatology (Oxford). 2022;61:1276\u201381.","journal-title":"Rheumatology (Oxford)"},{"key":"1189_CR10","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3390\/biomedicines9081012","volume":"9","author":"Y Kawamura","year":"2021","unstructured":"Kawamura Y, Nakayama A, Shimizu S, et al. A proposal for practical diagnosis of renal hypouricemia: evidenced from genetic studies of nonfunctional variants of URAT1\/SLC22A12 among 30,685 Japanese individuals. Biomedicines. 2021;9:1012.","journal-title":"Biomedicines"},{"key":"1189_CR11","doi-asserted-by":"publisher","first-page":"20148","DOI":"10.1038\/srep20148","volume":"6","author":"M Sakiyama","year":"2016","unstructured":"Sakiyama M, Matsuo H, Shimizu S, et al. The effects of URAT1\/SLC22A12 nonfunctional variants, R90H and W258X, on serum uric acid levels and gout\/hyperuricemia progression. Sci Rep. 2016;6:20148.","journal-title":"Sci Rep"},{"key":"1189_CR12","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.3390\/biomedicines10071696","volume":"10","author":"M Hakoda","year":"2022","unstructured":"Hakoda M, Ichida K. Genetic basis of the epidemiological features and clinical significance of renal hypouricemia. Biomedicines. 2022;10:1696.","journal-title":"Biomedicines"},{"key":"1189_CR13","doi-asserted-by":"publisher","first-page":"14360","DOI":"10.1038\/s41598-019-50798-6","volume":"9","author":"DH Cha","year":"2019","unstructured":"Cha DH, Gee HY, Cachau R, et al. Contribution of SLC22A12 on hypouricemia and its clinical significance for screening purposes. Sci Rep. 2019;9:14360.","journal-title":"Sci Rep"},{"key":"1189_CR14","doi-asserted-by":"publisher","first-page":"e28641","DOI":"10.1371\/journal.pone.0028641","volume":"6","author":"V Tasic","year":"2011","unstructured":"Tasic V, Hynes AM, Kitamura K, et al. Clinical and functional characterization of URAT1 variants. PLoS ONE. 2011;6:e28641.","journal-title":"PLoS ONE"},{"key":"1189_CR15","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10157-024-02558-8","volume":"29","author":"S Sugihara","year":"2025","unstructured":"Sugihara S, Yamamoto Y, Teramoto K, et al. Annual change in eGFR in renal hypouricemia: a retrospective pilot study. Clin Exp Nephrol. 2025;29:173\u201381.","journal-title":"Clin Exp Nephrol"},{"key":"1189_CR16","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S0090-4295(00)00518-5","volume":"55","author":"SY Nakada","year":"2000","unstructured":"Nakada SY, Hoff DG, Attai S, et al. Determination of stone composition by noncontrast spiral computed tomography in the clinical setting. Urology. 2000;55:816\u20139.","journal-title":"Urology"},{"key":"1189_CR17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/cpdd.1317","volume":"13","author":"T Takahashi","year":"2024","unstructured":"Takahashi T, Sasaki M, Shimizu T, Yamaguchi S. Changes in urinary uric acid concentration after dotinurad administration to patients with hyperuricemia: a post hoc analysis of two clinical trials in Japan. Clin Pharmacol Drug Dev. 2024;13:87\u201395.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1189_CR18","first-page":"578","volume":"65","author":"I Hisatome","year":"1993","unstructured":"Hisatome I, Tanaka Y, Kotake H, et al. Renal hypouricemia due to enhanced tubular secretion of urate associated with urolithiasis: successful treatment of urolithiasis by alkalization of urine K+, Na(+)-citrate. Nephron. 1993;65:578\u201382.","journal-title":"Nephron"},{"key":"1189_CR19","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000381106","volume":"41","author":"M Wakasugi","year":"2015","unstructured":"Wakasugi M, Kazama JJ, Narita I, et al. Association between hypouricemia and reduced kidney function: a cross-sectional population-based study in Japan. Am J Nephrol. 2015;41:138\u201346.","journal-title":"Am J Nephrol"},{"key":"1189_CR20","doi-asserted-by":"publisher","first-page":"e0176055","DOI":"10.1371\/journal.pone.0176055","volume":"12","author":"M Kuwabara","year":"2017","unstructured":"Kuwabara M, Niwa K, Ohtahara A, et al. Prevalence and complications of hypouricemia in a general population: a large-scale cross-sectional study in Japan. PLoS ONE. 2017;12:e0176055.","journal-title":"PLoS ONE"},{"key":"1189_CR21","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.3390\/biomedicines9121847","volume":"9","author":"M Hosoyamada","year":"2021","unstructured":"Hosoyamada M. Hypothetical mechanism of exercise-induced acute kidney injury associated with renal hypouricemia. Biomedicines. 2021;9:1847.","journal-title":"Biomedicines"},{"key":"1189_CR22","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s40620-022-01494-8","volume":"36","author":"T Mazzierli","year":"2023","unstructured":"Mazzierli T, Cirillo L, Palazzo VR, et al. Clinical features suggesting renal hypouricemia as the cause of acute kidney injury: a case report and review of the literature. J Nephrol. 2023;36:651\u20137.","journal-title":"J Nephrol."},{"key":"1189_CR23","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1093\/ndt\/gfh094","volume":"19","author":"T Ohta","year":"2004","unstructured":"Ohta T, Sakano T, Igarashi T, et al. Exercise-induced acute renal failure associated with renal hypouricaemia: results of a questionnaire-based survey in Japan. Nephrol Dial Transplant. 2004;19:1447\u201353.","journal-title":"Nephrol Dial Transplant"},{"key":"1189_CR24","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s00467-008-1032-6","volume":"24","author":"K Kaneko","year":"2009","unstructured":"Kaneko K, Taniguchi N, Tanabe Y, et al. Oxidative imbalance in idiopathic renal hypouricemia. Pediatr Nephrol. 2009;24:869\u201371.","journal-title":"Pediatr Nephrol"},{"key":"1189_CR25","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.3390\/biomedicines10071584","volume":"10","author":"D Miyamoto","year":"2022","unstructured":"Miyamoto D, Sato N, Nagata K, et al. Analysis of purine metabolism to elucidate the pathogenesis of acute kidney injury in renal hypouricemia. Biomedicines. 2022;10:1584.","journal-title":"Biomedicines"},{"key":"1189_CR26","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.2169\/internalmedicine.0457-22","volume":"62","author":"S Miyazaki","year":"2023","unstructured":"Miyazaki S, Hamada T, Isoyama T, et al. Characterization of urate metabolism and complications of patients with renal hypouricemia. Intern Med. 2023;62:1915\u201320.","journal-title":"Intern Med"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-026-01189-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-026-01189-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-026-01189-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:03:07Z","timestamp":1791925387000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-026-01189-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1189"],"URL":"https:\/\/doi.org\/10.1007\/s13730-026-01189-0","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"13 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NO has received research grants from Sato Pharmaceutical Co., Ltd. MK has received research grants from JSPS KAKENHI (20K17168, 23K07493, and 26K11018) and from the Japanese Society of Gout and Uric and Nucleic Acids. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committees at which the studies were conducted (IRB approval numbers: 21A048, 040301, and 040611) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for the publication of clinical information and images.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"149"}}